Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
Listen to this summary
This study aimed to evaluate the safety, tolerability, and preliminary efficacy of AC01, an oral ghrelin receptor agonist, in patients with heart failure with reduced ejection fraction (HFrEF). The results indicated that AC01 was generally safe and well tolerated over 28 days, with no major adverse events reported, suggesting potential for further investigation in larger trials.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Lancet (London, England)
View all →Jun 24, 2026 · Lancet (London, England)
Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial
Jun 23, 2026 · Lancet (London, England)
Non-invasive removal of the Smart tracheal occlusion device for fetal congenital diaphragmatic hernia: a single-arm, open-label, phase 1 study
Jun 23, 2026 · Lancet (London, England)
Combined bladder-kidney transplantation: first-in-human feasibility trial
Jun 18, 2026 · Lancet (London, England)
The UCL-Lancet Commission on Migration and Health: review of the state of progress
Jun 17, 2026 · Lancet (London, England)
Patellar resurfacing in total knee replacement: 20-year clinical and economic results of a large multicentre, randomised controlled trial in the UK
Jun 17, 2026 · Lancet (London, England)
Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data
More in Nuclear Medicine
View all →Jun 24, 2026 · The New England journal of medicine
A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis
Jun 24, 2026 · The New England journal of medicine
Prevention and Treatment of Peanut Allergy
Jun 24, 2026 · The New England journal of medicine
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
Jun 17, 2026 · The New England journal of medicine
Management of Differentiated Thyroid Cancer
Jun 17, 2026 · The New England journal of medicine
Cefazolin for Methicillin-Susceptible <em>Staphylococcus aureus</em> Bacteremia
Jun 15, 2026 · The New England journal of medicine
Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary Angioedema
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
